CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Orexigen Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
Suite 200
Phone: (858) 875-8600p:858 875-8600 La Jolla, CA  92037-1024  United States Fax: (858) 875-8650f:858 875-8650
This company's Plan of Liquidation went into effect on 5/31/2019
This company ceased filing statements with the SEC on 5/31/2019.
This company is no longer actively traded on any major stock exchange.
Business Summary
Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201712/31/2016YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Lota S.Zoth 59 7/27/2018 4/27/2012
President, Chief Administrative Officer, General Counsel, Treasurer, Secretary Thomas P.Lynch 50 7/27/2018 12/1/2015

Business Names
Business Name
OREX
Orexigen Therapeutics Inc.
Orexigen Therapeutics Ireland Limited
OREXQ

General Information
Number of Employees: 132 (As of 3/15/2017)
Outstanding Shares: 18,887,033 (As of 12/31/2017)
Shareholders: 21
Stock Exchange: OTC
Federal Tax Id: 651178822
Fax Number: (858) 875-8650


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, July 23, 2023